EFFICACY AND SAFETY OF PONATINIB USED IN FRAIL CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS OUTSIDE OF CLINICAL TRIALS

被引：0
|
作者：
Breccia, M. [1 ]
Abruzzese, E. [2 ]
Accurso, V. [3 ]
Castagnetti, F. [4 ]
Galimberti, S. [5 ]
Bonifacio, M. [6 ]
Gangemi, D. [7 ]
La Barba, G.
Sora, F. [8 ]
Tiribelli, M. [9 ]
Iurlo, A. [10 ]
Luciano, L. [11 ]
Gozzini, A. [12 ]
Pezzullo, L.
Rossi, A. Russo [13 ]
Sgherza, N. [14 ]
Foa, R. [1 ]
机构：
[1] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Policlin Umberto I, Hematol, Rome, Italy
[2] S Eugenio Hosp, Rome, Italy
[3] Policlin Giaccone, Hematol, Palermo, Italy
[4] Univ Bologna, Inst Hematol L&A Seragnoli, Univ Hosp, Bologna, Italy
[5] Pisa Univ, Hematol, Pisa, Italy
[6] Univ Verona, Sect Hematol, Dept Med, Verona, Italy
[7] Fabrizio Spaziano Hosp, Frosinone, Italy
[8] Cattolica Sacro Cuore Univ, Rome, Italy
[9] Udine Univ, Hematol, Udine, Italy
[10] Univ Milan, IRCCS Ca Granda Maggiore Policlin Hosp Fdn, Milan, Italy
[11] Federico II Univ Naples, Naples, Italy
[12] Univ Firenze, AOU Careggi, Florence, Italy
[13] Univ Bari, Hematol & Transplants Unit, Bari, Italy
[14] Casa Sollievo Sofferenza Hosp, San Giovanni Rotondo, Italy
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P096
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF SECOND LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
    Breccia, M.
    Abruzzese, E.
    Castagnetti, F.
    Bonifacio, M.
    Gangemi, D.
    Sora, F.
    Iurlo, A.
    Luciano, L.
    Gozzini, A.
    Gentile, M.
    Bocchia, M.
    Luzi, D.
    Maggi, A.
    Sgherza, N.
    Isidori, A.
    Crugnola, M.
    Pregno, P.
    Foa, R.
    HAEMATOLOGICA, 2017, 102 : 89 - 89
  • [2] A NATIONWIDE OBSERVATIONAL STUDY OF THE ISRAELI EXPERIENCE WITH PONATINIB OUTSIDE CLINICAL TRIALS IN CHRONIC MYELOID LEUKEMIA
    Abulafia, A. Shacham
    Raanani, P.
    Lavie, D.
    Volchek, Y.
    Ram, R.
    Hellmann, I.
    Shargian, L.
    Gourevietch, A.
    Chubar, E.
    Ratzon, R.
    Rozovski, U.
    HAEMATOLOGICA, 2016, 101 : 742 - 743
  • [3] A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia
    Abulafia, Adi Shacham
    Raanani, Pia
    Lavie, David
    Volchek, Yulia
    Ram, Ron
    Hellmann, Ilana
    Shargian, Liat
    Gourevietch, Anna
    Chubar, Evgeni
    Ratzon, Roy
    Rozovski, Uri
    BLOOD, 2015, 126 (23)
  • [4] Evaluation of Efficacy and Safety of Ponatinib as Third-line Treatment in Patients with the Diagnosis of Chronic Phase Chronic Myeloid Leukemia
    Patir, Pusem
    Soyer, Nur
    Vural, Filiz
    Saydam, Guray
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2016, 26 (04): : 224 - 226
  • [5] Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
    Luciano, Luigia
    Latagliata, Roberto
    Gugliotta, Gabriele
    Annunziata, Mario
    Tiribelli, Mario
    Martino, Bruno
    Sica, Antonello
    Esposito, Maria Rosaria
    Bocchia, Monica
    Galimberti, Sara
    Sora, Federica
    Albano, Francesco
    Palmieri, Raffaele
    Pregno, Patrizia
    Dragani, Matteo
    Iovine, Maria
    Sica, Simona
    Iurlo, Alessandra
    Castagnetti, Fausto
    Rosti, Gianantonio
    Breccia, Massimo
    ANNALS OF HEMATOLOGY, 2023, 102 (06) : 1375 - 1382
  • [6] Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
    Luigia Luciano
    Roberto Latagliata
    Gabriele Gugliotta
    Mario Annunziata
    Mario Tiribelli
    Bruno Martino
    Antonello Sica
    Maria Rosaria Esposito
    Monica Bocchia
    Sara Galimberti
    Federica Sorà
    Francesco Albano
    Raffaele Palmieri
    Patrizia Pregno
    Matteo Dragani
    Maria Iovine
    Simona Sica
    Alessandra Iurlo
    Fausto Castagnetti
    Gianantonio Rosti
    Massimo Breccia
    Annals of Hematology, 2023, 102 : 1375 - 1382
  • [7] A NATIONWIDE OBSERVATIONAL STUDY OF PONATINIB IN CHRONIC MYELOCYTIC LEUKEMIA OUTSIDE CLINICAL TRIALS
    Abulafia, A. Shacham
    Ratzon, R.
    Lavie, D.
    Volchek, Y.
    Ram, R.
    Hellman, I.
    Shargian, L.
    Gourevietch, A.
    Chubar, E.
    Koren-Michowitz, M.
    Zilbershats, I.
    Raanani, P.
    Rozovski, U.
    HAEMATOLOGICA, 2017, 102 : 732 - 733
  • [8] Analysis of Adverse Events of Dasatinib and Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated Outside Clinical Trials
    Suh, Koung Jin
    Lee, Ji Yun
    Shin, Dong-Yeop
    Koh, Youngil
    Bang, Soo-Mee
    Yoon, Sung-Soo
    Park, Seonyang
    Kim, Inho
    Lee, Jeong-Ok
    BLOOD, 2016, 128 (22)
  • [9] Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Kim, Dong-Wook
    Pinilla-Ibarz, Javier
    le Coutre, Philipp D.
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Apperley, Jane F.
    Khoury, H. Jean
    Talpaz, Moshe
    DiPersio, John F.
    DeAngelo, Daniel J.
    Abruzzese, Elisabetta
    Rea, Delphine
    Baccarani, Michele
    Mueller, Martin C.
    Gambacorti-Passerini, Carlo
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Guilhot, Francois
    Deininger, Michael W.
    Hochhaus, Andreas
    Hughes, Timothy P.
    Goldman, John M.
    Shah, Neil P.
    BLOOD, 2013, 122 (21)
  • [10] Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia
    Huguet, Francoise
    Rea, Delphine
    Cayssials, Emilie
    Etienne, Gabriel
    Nicolini, Franck-Emmanuel
    EXPERT REVIEW OF HEMATOLOGY, 2023,
12345